Chemoforma Ltd.Chemoforma Ltd.

Trials in Pig / List of trials

We recommend using 2000 g of ASCOGEN® / tonne of feed before weaning and 1000 g of ASCOGEN® / tonne of feed until 40 days after weaning.

ASCOGEN® an exceptional feed supplement

ASCOGEN® is a unique formulation of purified RNA and purified nucleotides.

Although not yet defined as essential nutrients, numerous scientifically confirmed trials demonstrated that purified nucleic acids must be regarded as a management tool to control stress and disease while maintaining or enhancing performance in agricultural livestock. Having been successfully used in all such applications, and more, they foster development, participate in cellular and molecular repair mechanisms and ensure unhindered cell proliferation without affecting growth, development or reproduction upon environmental, physical and pathogenic challenges.

Recommended dosages
Suckling piglets:     2000 g / tonne of feed
Weaners:               1000 g / tonne of feed until 40 days after weaning
Sows:                      500 g / tonne of feed during the whole year
or:
Lactating sows:    3 g per animal daily
Pregnant sows:     2 g per animal daily

Withdrawal period
None

Stability
ASCOGEN® is heat resistant and can be mixed with feed before pelleting or extruding

Packaging
ASCOGEN® is packed in 25kg polyethylene-lined white 5-ply paper bags

Trials in Pig

Effects of ASCOGEN® on performance and immune response in piglets


A dose-dependent increase in the daily weight gain became obvious in this trial in piglets. The effects of PSB-Complex® were more distinct when including 1000 g of ASCOGEN® / tonne of feed compared to 500 g. Moreover the morphological differences directly reflect the inclusion rate of ASCOGEN®. While the inclusion of 500 g / tonne of feed only affects the height of duodenal villi, an additional significant effect on the Jejunum is visible after inclusion of 1000 g / tonne of feed. Hypothetically, the active ingredients of ASCOGEN® are already exhausted in the Duodenum at 500 g / tonne of feed while further significantly improved Jejunum morphology is evident at inclusion of 1000 g of ASCOGEN® / tonne of feed.


An increase in specific Immunoglobulins was apparent in both trial groups with ASCOGEN® after stimulation of the immune system with LPS (lipopolysaccharide). The increase was more rapid and pronounced in the 1000 g of ASCOGEN® / tonne of feed group compared to the 500 g group. In both trial groups, the IgG’s were substantially increased. Even more pronounced was the effect on the specific Foot-and-Mouth-Disease-neutralizing antibodies after vaccination against FMD. Three weeks after vaccination, the antibody titre in the 1000 g of ASCOGEN® / tonne of feed group was still 4 times higher than the vaccinated control. 

This trial clearly demonstrates the positive effects of ASCOGEN® on the performance upon immunological challenges in piglets.

ASCOGEN® shows a dose-dependant increase in performance


Dose-dependent increase in average daily weight gain of piglets in a period of 68 days (89 days of age).


Dose-dependent final weight of piglets after 68 days. The inclusion of 2000 g of ASCOGEN® / tonne of feed achieved the highest weight in this experiment.



The feed conversion ratio showed a linear course in this experiment. The facilitated development of the intestinal tract with ASCOGEN® as well as the increase of the active intestinal surface area, lead to an improved FCR.

ASCOGEN® enhances the performance of piglets upon severe enteritic problems


Four different groups were used in this trial. The total length of the trial was 50 days, and feeding of 2000 g of ASCOGEN® / tonne of feed in group 2 started 7 days before weaning until weaning. The second trial group received ASCOGEN® for 25 days from weaning and the third trial group was fed with fortified feed for 32 days starting 7 days before weaning.


Performance data of piglets with severe enteritic problems. It was determined that feeding should start as early as possible in piglets in order to actively support the development of organs and the immune system. The best results however are achieved when feeding ASCOGEN® before and after weaning.


List of trials

2007                 Spain
Dose-titration of nucleotides in nursery pig diets

2007                 LUDGE MEER
Performance results

2007                 China
ASCOGEN® trial report

2005                 Ukraine
Benefits of ASCOGEN® on the performance of piglets

2005                 Slovenia
Effect of nucleotide supplementation on lymphocyte DNA damage induced by dietary oxidative stress in pigs

2005                 Thailand
ASCOGEN®-piglets trial

2005                 USA
Dr. Mateo: Aspect of nucleotide nutrition in pigs

2004                 Brazil
Effect of ASCOGEN® on the partial replacement in piglet feed

2001 / 2002      Taiwan
Trial report for ASCOGEN® at the Tiger Mountain Farm

2000                 Switzerland
Effect of ASCOGEN® on the performance of sows and piglets under the influence of ASCOGEN®

2000                 Switzerland
The insertion of 0.4 % of ASCOGEN® on sows and piglets

2000                 ESSAI EARL DU PONTCEAU / GAEC QUEDRAIRIE
Follow up of the technical results on sow fed with ASCOGEN®  and the evolution of their piglets

1999                 Philippines
Evaluation of stillbirth, runts (below 900 gr), birth weight, litter size, mortality

1998                 MEDISCH LABO BRUYLAND
Results for CK and LDH

1997                 Philippines
Efficacy of ASCOGEN® as biogenic performance enhancer in sow and piglets

1997                 France
Results in feeding piglets

1997                 The Netherlands
Influenza and Aujesky virus

1996                 The Netherlands
PROVIMI PAKT OEDEEMZIEKTE AAN VIA HET VOEDER

1996                 The Netherlands
Provimi tackles the Oedema disease through feed

1996                 AGROKOMBINAT SUBOTICA ING. TOMICIC
Effect of ASCOGEN® on the fertility of sow

1995 / 1996      The Netherlands
Trial with 150 sows, experiences with ASCOGEN®

1995                 Hungary
The ASCOGEN® biological performance enhancers in pig production

1995                 Slovenia
Trial report of usage Farmatan in combination with ASCOGEN®: trial with piglets

1995                 Philippines
Trial results on ASCOGEN®, farrowing rate, litter size, average birth weight, average weaning weight, number of piglets weaned, mortality

1995                 Belgium
Trial with piglets, costs of medicines, feed conversion, mortality

1994 / 1995      The Netherlands
Trial in piglets, body weight, mortality, cost of medicines, feed conversion

1994 / 1995      Slovenia
Pig trial, weighing, feed consumption

1994                 The Netherlands
Trial with piglets

1994                 Hungary
Effect of ASCOGEN® on stress parameters in fattening pigs

1994                 Hungary
Proceeding of the 3rd international symposium on animal nutrition Kaposvar (HU) stress in pigs going for slaughter

1993                 Hungary
A GENIUM-S HOZAMFOKOZOVAL GIMSZARVASOKBAN VEGZETT KISERLET EREDMENYEI

1993                 United Kingdom
Flatdeck feed trial

1992                 Switzerland
Demonstration of the effectiveness in a long-term trial

1992                 Austria
Efficacy of ASCOGEN® on the capacity of reproduction on sows and on piglets breeding

1992                 Austria
Examination of the effect of ASCOGEN® on the specific immune response and blood status on fattened pigs

1992                 France
Trial with sows

1992                 The Netherlands
Effect on sows

1992                 France
Effect on sows

1992                 Switzerland
TESTEN AUF IGG UND SPEZ.AK

1992                 United Kingdom
Effects on white cell production in breeding pigs under disease stress condition

1991                 Switzerland
Effect on pig fattening

1991                 Ireland
Effect on pigs

1991                 Hungary
Effect of ASCOGEN® on the response of Zearalenon (F2-Toxin) on young sows

1990-1992         Switzerland
Effect on pig fattening with ASCOGEN®

1990 / 1991      Austria
Effect on the immune response of pigs vaccinated with Parvovirus

1989                 Malaysia
Trial on commercial pig farm, farm affected by swine Enzootic Pneumonia

1989                 Australia
Effect on growth rate and feed conversion efficiency in weaner and grower pigs

1988                 Germany
Effect of ASCOGEN® on the growth and intestinal flora of pigs

1987 / 1988      United Kingdom
Effects on pig reproduction and fattening

1982 / 1983      Philippines
Performance of piglets from birth to weaning (26 days) initial litter (sows fed with ASCOGEN® in second part of the pregnancy) life cycle feeding trials of ASCOGEN®

1978                 Tschech Republic
Comparison of ASCOGEN® with a negative and a positive control (Caradox)

1968                 Germany
Final report of test with ASCOGEN®

NO DATE          TIGER MOUNTAIN FARM
To evaluate the efficacy of ASCOGEN® in improving swine general health condition

NO DATE          TESGOFARM BV
Mortality of piglets

NO DATE          USA
Effects of ASCOGEN® on faecal microbiology on young growing pigs and rats

NO DATE          NO INDICATION
Examination of the influence of ASCOGEN® to slaughtering quality of fattening pigs

NO DATE          United Kingdom
ASCOGEN® with Mycoplasma vaccination

NO DATE          Brazil
TESTE NUCLEOTAIDE COM SUINOS Ö AURORA hyperlink trials\NUCLEOTAID-SUÍNOS II(1)1.doc

NO DATE          Switzerland
Trial of therapeutic antibodies for the symptomatic treatment of diarrhoea in piglets and calves

NO DATE          Belgium
Results from trials of ASCOGEN® on Blue Ears disease in pigs

RESTRICTED AREA: No information availbale at the moment